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Failed regeneration of central nervous system myelin contributes to clinical decline in 2 
neuroinflammatory and neurodegenerative diseases, for which there is an unmet therapeutic need. 3 
Here, we reveal that efficient remyelination requires death of pro-inflammatory microglia followed by 4 
repopulation to a pro-regenerative state. We propose that impaired microglia death and/or 5 
repopulation may underpin dysregulated microglia activation in neurological diseases, and reveal 6 
novel therapeutic targets to promote white matter regeneration.  7 
3 
 
Main text: 8 
Central nervous system (CNS) remyelination reinstates axon health and function1-3, yet fails in 9 
prevalent neurodegenerative disorders contributing to axon dysfunction/loss4-6 for which there is an 10 
unmet therapeutic need. These disorders (e.g. multiple sclerosis, ALS, spinal cord injury) are 11 
associated with chronic activation of the resident immune cells, microglia7-10. Effective resolution of 12 
pro-inflammatory microglia activation (iNOS+ TNFα+ CCL2+) via a transition to a pro-regenerative 13 
microglia state (Arg-1+ CD206+ IGF-1+) initiates remyelination8. Remyelination is impaired when 14 
this transition is either prevented (by targeted depletion of pro-regenerative microglia), or when it 15 
fails, as identified by prolonged pro-inflammatory microglia presence in aged mice and chronic 16 
human brain lesions8. However, the mechanisms underpinning this transition in microglia activation 17 
remain unknown.  18 
To reveal these mechanisms, we performed RNA sequencing of microglia isolated from focal 19 
demyelinated lesions of young adult mouse corpus callosum induced with the myelin toxin 20 
lysophosphatidyl choline (LPC), where regeneration occurs without concomitant damage and the 21 
timing of microglia activation has been previously defined (Fig. 1A)8. At the peak of pro-22 
inflammatory (3 dpl) and pro-regenerative microglia activation (10 dpl), microglia were FACS-23 
isolated based on expression of CD11b, lack of expression of neutrophil and T lymphocyte markers 24 
(Ly6G, CD3), and low expression of CD45 (gating strategy in Supplementary Fig.1A); use of 25 
differential CD45 expression (on the logarithmic scale) to distinguish between microglia (lo) and 26 
infiltrating monocyte-derived macrophages (hi) in white matter injury has been previously validated 27 
using transgenic reporters and bone marrow chimeras11-15. Cells expressed microglia signature genes 28 
at both time points post-demyelination (Supplementary Fig.1B); we assessed regulation of two of 29 
these genes (P2ry12, Csf1r) after demyelination versus non-lesion microglia by qPCR, and observed 30 
no significant change at 3 dpl yet subsequent upregulation at 10 dpl (Supplemental Fig.1C). Cells did 31 
not express markers for border-associated macrophages or monocyte-derived cells16,17(Supplementary 32 
Fig.1D). Of the 5000 most highly expressed genes for each time point (including non-differentially 33 
expressed genes), 57.2% were shared and 21.4% were specific to each time point (Fig. 1B). Microglia 34 
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also expressed some genes associated with neonatal microglia during developmental myelination18,19 35 
(Supplementary Fig. 1E, F) or adult microglia during neurodegeneration20,21 (Supplementary Fig. 1G-36 
I), some of which were significantly enriched in microglia at 10 dpl. 1020 genes were significantly 37 
differentially expressed between 3 and 10 dpl (p<0.05) (Fig. 1C; Log2 fold change in Supplementary 38 
Sheet 1), indicating differing functions. These included genes involved in survival/ proliferation 39 
(Birc5, Smad2, Ccnb1), anti-oxidant responses (Keap1), inflammation (Tnfrsf1b, Jak2, Nfkbid, 40 
Cryba1, Gpmnb, Socs1, Cd40), remyelination (Axl, Osm, Adam8), and associated with microglia in 41 
neurodegeneration (Msr1, Hdac5, Syp) (Supplementary Fig. 1J). Gene Ontology (GO) term 42 
enrichment analysis identified differential regulation of the immune response, with 3 dpl microglia 43 
showing ‘positive regulation of chronic inflammatory responses’, whereas 10 dpl microglia showed 44 
‘positive regulation of Th2 cell cytokine production’, ‘positive regulation of IL-10 secretion’, and 45 
‘positive regulation of IL-13 secretion’ (Supplementary Fig. 2), suggesting pro- and anti-46 
inflammatory functions, respectively. Accordingly, transcriptional regulators upregulated at 10 dpl 47 
[identified using Ingenuity Pathway Analysis (IPA)] included those with anti-inflammatory function 48 
(Bcl6, Grhl1, Tle1, Nfkbid) (Supplementary Table 1; Supplementary Fig. 1K). Significantly 49 
upregulated genes at 10 dpl included those previously shown to directly regulate remyelination/ 50 
nervous system regeneration (Matn2, Osm, Fgf1, Cd300lf), those associated with myelination (Bmp1, 51 
Cd69, Fabp5), and those which control pathways that support oligodendrocyte lineage cell responses 52 
[iron export (Cp), Wnt pathway inhibition (Nit1)] (Fig.1D, Supplementary Fig. 1L). This suggests a 53 
complex contribution of pro-regenerative microglia to remyelination via establishment of a supportive 54 
microenvironment. Both 3 dpl and 10 dpl microglia showed significant engagement of phagocytic 55 
pathways, as identified by KEGG analysis (‘fat digestion’ at 3 dpl; ‘endocytosis’ at 10 dpl; Fig. 1E) 56 
and GO terms (e.g. ‘degradation of lipoproteins’ at 3dpl; ‘structural constituent of myelin sheath’ at 57 
10 dpl; Supplementary Fig.2), suggesting engulfment and/or breakdown of myelin debris throughout 58 
remyelination, as previously shown22-24. Accordingly, receptors associated with myelin debris 59 
phagocytosis during remyelination were expressed at both time points (Fig. 1F).  60 
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We found enrichment of cell death-associated pathways in microglia at 3 dpl. First, KEGG 61 
pathway analysis identified ‘axon guidance’ and ‘colorectal cancer’ pathways to be engaged which 62 
were associated with genes regulating cell death (Birc5, Smad2, Ephrb1/2) (Fig. 1E). Second, IPA 63 
analysis identified ‘Cell death & Survival’ as a major molecular and cellular function (Fig. 1G), due 64 
to regulation of genes associated with death pathways such as TNF receptor signalling25, TRAIL26, 65 
and p53 (Supplementary Table 2). Third, the majority of transcriptional regulators upregulated at 3 66 
dpl are known to control cell death (Supplementary Table 1; Supplementary Fig. 1M). To determine 67 
whether microglia undergo death after demyelination, we analysed IBA-1+ cells in lesions. We 68 
observed a change in the distribution of IBA-1+ cells over time, which was homogenous at 3 dpl, 69 
sparse at 7 dpl, and clustered at 10 dpl (Fig. 1I). The density of IBA-1+ cells was decreased at 7 days 70 
post-LPC (dpl) (Fig.1H, I), a time intermediate to the peaks in pro-inflammatory microglia (3 dpl) and 71 
pro-regenerative microglia (10 dpl), such that this was no longer significantly different from sham 72 
control. This represented cell death, as flow cytometric analysis of microglia (Cd11b+ Cd45lo) death 73 
(Annexin-V+ 7-AAD+) revealed an increase at 7 dpl (Fig. 1J, K; gating strategy Supplementary Fig. 74 
3A; Supplementary Fig. 3C). Microglia isolated from sham-lesioned mice at 7 days post-surgery were 75 
negative for Annexin-V and 7-AAD (Supplementary Fig. 3B), excluding the possibility that death 76 
occurred consequent to injection or cell isolation. Thus, after demyelination and prior to onset of 77 
efficient remyelination, microglia die during the transition from pro-inflammatory to pro-regenerative 78 
activation. 79 
To investigate mechanisms regulating microglia death after demyelination, we first used ex 80 
vivo mouse organotypic cerebellar slice cultures which mimic the tissue microenvironment and 81 
remyelination seen in vivo27, yet are amenable to precise time courses and live imaging of deep brain 82 
white matter (Supplementary Fig. 4A). Consistent with observations in vivo, microglia (CD68+, 83 
PU.1+, IBA-1+) in LPC-demyelinated slices were decreased by 1 dpl, intermediate to the peaks in 84 
pro-inflammatory microglia (iNOS+ CD68+; 0.5 dpl) and pro-regenerative microglia (Arg-1+ 85 
CD68+; 7 dpl) (Supplementary Fig. 4B-F). Vehicle (PBS)-treated explants showed no demyelination 86 
(Supplementary Fig. 4G) nor iNOS+ CD68+ cells (Supplementary Fig.4H) at any time, with MBP 87 
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immunoreactivity comparable to fully myelinated untreated slices (Supplementary Fig. 4I). Live 88 
incorporation of a marker of compromised membrane integrity (propidium iodide; PI) confirmed 89 
microglia death prior to cell loss (18-24 hours post-LPC (hpl); Supplementary Fig. 4J-M) and PI was 90 
present in the vast majority of PU.1+ microglia nuclei by 24 hpl (Supplementary Fig. 4M). We ruled 91 
out microglia death via toxic effects of LPC, as no cell loss was observed when primary microglia 92 
cultures were treated with LPC overnight (Supplementary Fig. 5A). Live imaging of explants derived 93 
from mice in which microglia are eGFP+ (Csf1r-eGFP; MacGreen) showed microglia rounding up 94 
and rupturing post-LPC, which was not observed in non-demyelinated explants (Supplementary 95 
Videos S1, S2). However, microglia were negative for the apoptotic markers cleaved caspase-3 and 96 
TUNEL (Supplementary Fig. 5B), yet constitutively positive for the pyroptosis marker cleaved 97 
caspase-1 (Supplementary Fig. 5C) suggesting the involvement of the latter in non-death-associated 98 
pathways28. We then investigated necroptosis, a programmed necrosis whereby a necroptosome 99 
complex composed of RIPK1, RIPK3, and MLKL compromises membrane integrity29,30. Necroptosis 100 
markers were expressed in IBA-1+ or CD68+ cells after demyelination at time points prior to their 101 
death: at 3 dpl in vivo (Fig. 2A-C; Supplementary Fig.5D; IBA-1 and MLKL co-localization: 34.2 % 102 
at 3 dpl vs 7.0 % at 7 dpl) and 12 hpl in slices (Fig. 2D, E). Although some CD68+ cells were present 103 
in sham-injected mice in vivo, these were RIPK3-negative (Fig. 2A).  Additionally, several genes that 104 
regulate necroptosis were enriched in the ‘Cell death & Survival’ pathways identified by IPA analysis 105 
(Tnfsf10, Gadd45a, Jak2, Socs1, Bcl3, Birc5, Cd40, Ppm1d, Rcan1, Tnfrsf1b, Msra, Slamf7, Comp, 106 
Hspa1b) (Supplementary Table 2). Using lineage tracing of infiltrating monocyte-derived 107 
macrophages via Ccr2-driven RFP expression, we confirmed that the majority of RIPK3+ cells in 108 
lesions in vivo were RFP- rather than blood monocyte-derived (RFP+) (Supplementary Fig. 6A-C). 109 
Additionally, CD68 staining in lesions strongly co-localized with the microglial marker Tmem119 110 
(Supplementary Fig.6D, E). We confirmed that microglia necroptosis is a common feature of 111 
remyelination by analysing 2 additional in vivo models of demyelination. In the cuprizone toxin-diet 112 
model31, RIPK3+ and MLKL+ microglia were significantly increased at the onset of remyelination, 113 
and decreased once remyelination was complete at 4 weeks on normal diet (Supplementary Fig. 7A-114 
D). Mining of published study on microglia transcriptomes from a model of chronic myelin injury to 115 
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the spinal cord [MOG-induced experimental autoimmune encephalomyelitis (EAE)]32 indicated 116 
expression of both Ripk3 and Mlkl at late stages of disease, when remyelination takes place in this 117 
model33 (Supplementary Fig. 7E). Therefore, microglia necroptosis appears to be associated with the 118 
onset of remyelination, regardless of CNS region or mode of injury.  119 
To determine the role of microglia necroptosis in remyelination, we used necrostatin-1, a 120 
small molecule which prevents necroptosome activity34. At 1 dpl, necrostatin-1 treatment of 121 
demyelinated slices prevented the loss of CD68+ microglia (Fig. 2F) and maintained iNOS+ CD68+ 122 
microglia numbers (Fig. 2G-H). The latter were still prominent at 7 dpl when the transition to the pro-123 
regenerative phenotype would normally have taken place (Fig. 2G, H); we did however observe a 124 
subsequent decrease in iNOS+ CD68+ cell numbers by 14 dpl (Fig. 2G) which may indicate either a 125 
delayed change in activation or apoptosis as a consequence of prolonged necroptosis inhibition35. 126 
Importantly, necrostatin-1 treatment significantly hindered remyelination at 7 and 14 dpl compared to 127 
the robust remyelination observed in the vehicle control (Fig. 2I, J). This effect did not result from 128 
directly inhibiting oligodendrocyte or neuronal necroptosis, documented during prolonged 129 
experimental demyelination/ in multiple sclerosis cortical lesions36 or in Alzheimer’s disease37, 130 
respectively, as only ~3% of oligodendrocyte lineage cells (Olig2+) or neurons (NeuN+) were 131 
RIPK3+ post-LPC in slices (Supplementary Fig. 8A-D). We confirmed that necrostatin-1 treatment in 132 
undemyelinated slices had no consequence on MBP immunoreactivity or iNOS expression in CD68+ 133 
microglia (Supplementary Fig.8E, F). To determine whether microglia necroptosis is also required for 134 
efficient remyelination in vivo, we aimed to specifically target necrostatin to macrophages by 135 
encapsulation in lipidic nanocapsules (LNCs) which were predicted to be preferentially taken up by 136 
phagocytes, as has been shown with other lipid-rich nanoparticle formulations8,22,38,39 (Fig.2K). 137 
Specificity of uptake in lesions was verified by injection of DiD-labelled LNCs, with >90% of DiD 138 
clusters co-localized with IBA-1+ cells (Fig.2L, N), significantly more than the percentage of clusters 139 
co-localized with other cell types with phagocytic capacity [3.9% of clusters in astrocytes (GFAP+; 140 
Fig. 2L, N) and 1.3% of clusters in oligodendrocyte lineage cells (CC1+, Olig1+; Fig.2N, 141 
Supplementary Fig. 8G, H)]. 3D reconstruction confirmed the internalization of DiD-LNCs within 142 
IBA-1+ cells (Fig. 2M; Supplementary Fig.8H). At 3 dpl, necrostatin-loaded LNCs inhibited 143 
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microglia necroptosis as indicated by decreased MLKL staining in IBA-1+ cells compared to vehicle 144 
(DMSO)-LNCs (Fig. 2O), reducing co-localization of MLKL and IBA-1 from 45.11% to 20.93%. 145 
Necrostatin-LNCs did not affect percentage of RIPK3+ CD68+ cells (Supplementary Fig. 8I), as 146 
expected given that necrostatin does not prevent RIPK3 expression but rather acts downstream to 147 
inhibit MLKL recruitment and activation40,41. Necrostatin-LNCs caused a relative increase in the 148 
number of Tmem119+ cells compared to vehicle LNCs (Fig. 2P), associated with an increased 149 
percentage of CD68+ cells expressing iNOS and decreased percentage of those expressing Arg-1 (Fig. 150 
2P). The increased microglia number was not consequent to enhanced proliferation, as Ki67+ PU.1+ 151 
cell number was significantly downregulated at 3 dpl in Necrostatin-LNC-treated lesions relative to 152 
vehicle-LNC control, then negligible in both conditions by 10 dpl (Supplementary Fig. 8J). 153 
Remyelination was impaired at 10 dpl following necrostatin-LNC treatment as indicated by reduced 154 
expression of the early remyelination marker myelin associated glycoprotein (MAG) (Fig.2Q, R). 155 
This impairment was not due to accumulation of myelin debris (identified using MBP which is not yet 156 
expressed at this early stage of remyelination) which was equally cleared in both LNC-treatment 157 
conditions (Supplementary Fig. 8K), consistent with our RNA sequencing data suggesting phagocytic 158 
capacity of pro-inflammatory microglia (Fig.1E, F; Supplementary Fig.2). Altogether, this data 159 
demonstrates the requirement for microglia necroptosis for efficient remyelination to take place. 160 
Having shown that lesion microglia die early-on following demyelination, we next 161 
determined how these repopulate to the pro-regenerative phenotype. We first assessed Nestin 162 
expression, shown to identify repopulating microglia following their experimental depletion in 163 
healthy brain42-44. In vivo focal lesions of the corpus callosum showed an increase in co-localization of 164 
IBA-1 with Nestin from 3 dpl to 7 dpl, which was reduced by 10 dpl when the transition in microglia 165 
activation has taken place (Fig. 3A-C). Little to no Nestin was co-localized with IBA-1 in sham 166 
control, indicating its expression by microglia largely during remyelination (Fig.3A). Microglia 167 
repopulation following experimental depletion has been proposed to occur via two mechanisms: i) de 168 
novo differentiation of CNS-resident Nestin+ cells43, or ii) proliferation of residual microglia which 169 
did not die42,44. However, these studies only examined microglia repopulation in otherwise healthy 170 
grey matter, where the microenvironment is likely to differ from focally injured white matter. Thus, to 171 
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determine to what extent these mechanisms account for microglia repopulation following 172 
demyelination, we performed lineage tracing.  We induced focal lesions in vivo in mice in which 173 
Nestin promoter-driven tdTomato (tdT) expression is inducible (Nes-CreERT2;RCL-tdT), allowing 174 
labelling of Nestin+ cells prior to demyelination. Of all tdT+ cells, the proportion which were Cd11b+ 175 
Cd45lo (gating Supplementary Fig. 9A) increased from 3 dpl to 7 and 10 dpl (Fig. 3D, E; 176 
Supplementary Fig. 9B). Although the proportion of all Cd11b+ Cd45lo cells which were tdT+ was 177 
increased at 7 dpl in comparison to 3 dpl and sham control, these only represented <5% of total 178 
microglia (Fig. 3F, G) suggesting that repopulation in vivo is mediated primarily by residual 179 
microglia.  180 
In the ex vivo model, we observed repopulation of both CD68+ cells (Supplementary Fig.4C) 181 
and PU.1+ cells (from 17 ± 3 cells/field at 24 hpl to 38 ± 1 cells/field at 3 dpl). Following 4-182 
hydroxytamoxifen-induced tdT expression in Nestin+ cells in slices derived from Nes-CreERT2;RCL-183 
tdT mice (recombination prior to LPC treatment; Supplementary Fig. 9C, D), we detected tdT+ IBA-184 
1+ cells only during repopulation (1-2 dpl), albeit at a higher proportion than observed in vivo (35% 185 
of all IBA-1+ cells at 2 dpl) (Supplementary Fig.9E, F). However, their presence was transient as they 186 
were not detected by 7 dpl (Supplementary Fig. 9E). Interestingly, tdT+ cells expressed neural stem 187 
cell markers Musashi-1 and Sox2, but were negative for GFAP (Supplementary Fig.9G). As a large 188 
proportion of IBA-1+ microglia were tdT negative, we assessed the contribution of residual microglia 189 
to repopulation using slices derived from Cx3cr1-CreER; RCL-tdT mice, in which tdT expression was 190 
induced in CX3CR1+ cells by 4-OHT (Supplementary Fig. 9H). tdT expression was detected in IBA-191 
1+ microglia (Supplementary Fig. 9I) but not the oligodendrocyte lineage which has been suggested 192 
to express CX3CR145 (Supplementary Fig. 9J). We confirmed that the majority of repopulated IBA-193 
1+ cells were tdT+ and therefore derived from residual microglia (Supplementary Fig.9K-M); 194 
Approximately 30% of the tdT+ cells were Nestin+ at 2dpl (Supplementary Fig.9N, O). As the entire 195 
explant is a lesion due to blanket LPC exposure, we can infer that repopulation following 196 
demyelination can occur from microglia within injured areas and does not require recruitment of 197 
microglia from non-lesion areas. Therefore, our lineage tracing supports that microglia repopulation 198 
during remyelination occurs primarily from residual microglia.  199 
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To investigate myeloid cell necroptosis and repopulation in human white matter disease, we 200 
examined multiple sclerosis (MS) lesion subtypes: i) active lesions, which have high densities of 201 
macrophages, positively correlated with remyelination46,47 and oligodendrocyte precursor 202 
abundance48, ii) chronic inactive lesions, which have low potential for remyelination, and iii) fully 203 
remyelinated lesions (Supplementary Table 3). Although densities of CD68+ cells undergoing 204 
necroptosis (RIPK3+ and MLKL+; Fig. 3H, I, K) or PU.1+ cells undergoing repopulation (Nestin+; 205 
Fig. 3J, L) were present in all MS lesion types, these were only significantly increased in active 206 
lesions compared to control tissue. This may suggest abundance of permissive cues for pro-207 
remyelination microglial responses in an inflammatory environment.  208 
We next investigated molecular pathways controlling microglia behaviour during 209 
remyelination. IPA analysis indicated Type-1 interferon (IFN) signalling as being significantly 210 
regulated in microglia during remyelination, with ‘Interferon signalling’ and ‘Role of JAK1, JAK2, 211 
and TYK2 signalling in Interferon signalling’ identified as top canonical pathways, and top predicted 212 
upstream regulators included IFNα/β, IFNAR, STAT1, IRF7, and IRF3 (P=0.00013, 0.00089, 213 
0.000045, 0.0071, 0.000086, respectively). We observed expression of the genes encoding the two 214 
chains of the IFN α/β receptor (Ifnar1, Ifnar2) and IFN-associated genes previously linked with 215 
microglia during remyelination49 (Supplementary Fig. 10A, B); The IFN receptor subunit IFNAR2 216 
was detected at the protein level in CD68+ cells in remyelinating lesions in vivo (Fig. 3M). IFN 217 
signalling, assessed by nuclear phospho-STAT1, was only active at 7 dpl in vivo and this was 218 
selective to PU.1+ nuclei (Fig. 3N). Only a subpopulation of PU.1+ nuclei were phospho-STAT1+ at 219 
7 dpl (58 ± 7%; Fig.3O), consistent with a recent single-cell sequencing study of microglia in this 220 
model at this time point which showed that the largest microglia sub-cluster (~60% of total) has an 221 
interferon signature 49. Given that at 7 dpl in the in vivo model microglia death and repopulation are 222 
concurrent, we assessed the role of Type-1 IFN signalling in either process using the brain explant 223 
demyelination model where these two responses are temporally separated (Supplementary Fig. 4C) 224 
and can thus be investigated in isolation. We blocked IFN receptor function using a neutralizing 225 
antibody against IFNAR2 and investigated effects on microglia number at the peak of microglia death 226 
(1 dpl) and repopulation (7 dpl) in explants. Anti-IFNAR2 treatment did not significantly affect 227 
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PU.1+ microglia numbers at 1 dpl compared to IgG isotype control (Fig. 3P), therefore did not 228 
prevent microglia death. However, a significant increase in PU.1+ cells from 1 dpl to 7 dpl was 229 
observed in control conditions but not following IFNAR2 blockade (Fig. 3P), suggesting impaired 230 
microglia repopulation in the latter. PU.1+ cells were significantly reduced in anti-IFNAR2 IgG 231 
conditions relative to control at 7 dpl (Fig. 3P, Q), and IBA-1+ cells were reduced to 37% of control 232 
(± 21) at this time. This was associated with a significant decrease in phospho-STAT1+ PU.1+ 233 
microglia at the peak of repopulation (7 dpl; Supplementary Fig. 10C), indicating effective inhibition 234 
of IFN signalling in microglia with IFNAR2 neutralization. Consequently, blocking IFNAR2 235 
impaired early remyelination at 7 dpl relative to control (Fig. 3R, S). Altogether, this data supports a 236 
regenerative role for Type-1 IFN signalling in regulating the repopulation of white matter microglia 237 
during efficient remyelination. 238 
In summary, our data reveal that remyelination is driven by coordination of pro-inflammatory 239 
microglia necroptosis and repopulation to a regenerative state. Whereas necroptosis of other cell types 240 
such as oligodendrocytes36 and neurons37 is associated with demyelination and neurodegeneration, 241 
respectively, here we show a novel regenerative role for necroptosis in rapidly shutting down pro-242 
inflammatory microglial activation to support remyelination. Although previous studies identified the 243 
capacity of microglia to repopulate following experimental depletion in healthy42-44, aged50, 244 
irradiated51, or neurodegenerating brain52, we now show that this feature can also serve to reinstate the 245 
microglia population after naturally occurring death following white matter injury, while regulating 246 
microglia activation. We reveal that microglia repopulation during white matter remyelination is 247 
positively regulated by Type-1 IFN signalling. This contrasts with its deleterious role in repopulated 248 
microglia selectively in grey matter following experimental depletion53- highlighting CNS region-249 
specific consequences of IFN signalling in microglia53,54- and complements findings of an IFN 250 
signature in microglia during recovery from facial nerve axotomy55. We propose that targeting pro-251 
inflammatory microglia death in neurological diseases may represent a novel strategy to dampen 252 
chronic CNS white matter inflammation, and support a regenerative response to reinstate myelin 253 
integrity.  254 
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Figures and Legends: 
 
Fig. 1. Microglia death occurs during transition in activation following in vivo demyelination. 
A. Microglia were isolated from focal demyelinated lesions induced by LPC injection into adult 
mouse corpus callosum, at 3 and 10 dpl representative of key time points of microglial activation 
during remyelination, for subsequent RNA sequencing.  
B. Overlap of top 5000 genes expressed by microglia (including non-significantly differentially 
expressed) at 3 and 10 dpl, ranked by average Fragments Per Kilobase of transcript per Million 
(FPKM).  
C. Heat map of gene expression level per sample relative to average expression across all samples. 
Red represents higher expression and blue represents lower expression.  
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D. Genes with a significant Log2 fold change (p<0.05) in 10 dpl vs 3 dpl microglia with known roles 
in regulating remyelination, myelination, and the oligodendrocyte lineage, represented as mean 
FPKM (± s.e.m.). *P=0.0174 (2-tailed paired Student’s t-test). 
E. Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways engaged in genes significantly 
differentially expressed (p<0.01) by microglia at 3 vs 10 dpl. KEGG pathways are represented on the 
Y axis and enrichment score on the X axis represented as –Log10(p) enrichment (p<0.05). 
F. Expression of genes associated with phagocytosis of myelin debris in microglia at 3 and 10 dpl, 
indicated as mean FPKM (± s.e.m.). No significance between time points, 2-tailed paired t-test. 
G. Ingenuity Pathway Analysis of significantly engaged molecular and cellular functions in microglia 
(p<0.05), indicating ‘Cell Death & Survival’ as a key pathway. 
H. Density of IBA-1+ cells per mm2 (± s.e.m.) of lesioned corpus callosum at 3, 7, and 10 dpl. 
*P=0.0486 for 3dpl, 0.011 for 10 dpl (one sampled t-test compared to average density in sham-
injected mice; indicated by the dotted line). 
I. Representative images of lesions in the corpus callosum stained for IBA-1 (green) and 
counterstained with Hoechst (blue). Scale bar, 50 µm. 
J. Flow cytometry plots of lesion-isolated microglia (Cd11b-PeCy7+ Cd45-BV605lo) positive for cell 
death markers Annexin-V-FITC and 7-AAD at 3, 7, and 10 dpl. 
K. Mean proportion of all microglia which are Annexin-V+ 7-AAD+ at 3, 7 and 10 dpl ± s.e.m. 
****P<0.0001 3dpl vs 7 dpl, *P=0.0233 7 dpl vs 10 dpl (2-tailed unpaired Student’s t-test).  






Fig. 2. Pro-inflammatory microglia undergo necroptosis prior to onset of remyelination. 
A. In vivo lesioned corpus callosum (dotted outline) at 3 and 7 dpl, along with a sham injection 
stained for RIPK3 (green) and CD68 (red). Inset at 3 dpl shows RIPK3+ CD68+ cell. Scale bar, 
50µm. 
B. Mean percentage of RIPK3+ CD68+ microglia / total CD68+ microglia at 3 and 7 dpl in in vivo 
lesioned corpus callosum ± s.e.m.. ***P=0.0002 (2-tailed unpaired Student’s t-test). N=3 mice per 
time point. 
C. Images of in vivo corpus callosum lesion stained for MLKL (red) and IBA-1 (green) at 3 dpl. 
Arrows indicate MLKL+ IBA-1+ cells. Scale bar, 10µm. 
D. Mean number of MLKL+ microglia (IBA-1+) at 0, 6 and 12 hpl in slices ± s.e.m.. *p<0.05 12 hpl 
vs 0 hpl (Kruskal-Wallis test, Dunn’s Multiple Comparison post-test). N=3 biological replicates. 
E. Untreated (0 hpl) and LPC-treated slices (12 hpl) immunostained for IBA-1 (green) and MLKL 
(red), double positive cells indicated (arrows). Magnified example of a selected IBA-1+ MLKL+ cell 
(box; right) at 12 hpl. Scale bar, 10 µm. 
F. Mean number of total microglia (CD68+) at 1 and 7 dpl in NEC-1- or VEH-treated slices ± s.e.m.. 
**P=0.0027 (2-tailed unpaired Student’s t-test). N=3 biological replicates per time point and 
condition. Images taken at magnification 20X. 
G. Mean number of iNOS+ microglia (CD68+) at 1, 7, and 14 dpl in NEC-1- or VEH-treated slices ± 
s.e.m.. *P=0.05 vs VEH (Mann-Whitney test). N=3 biological replicates per time point and condition.  
H. Demyelinated slices treated with vehicle (VEH; left) or necrostatin-1 (NEC-1; right) at 1 and 7 dpl 
immunostained for CD68 (red) and iNOS (green). Scale bar, 20 µm. 
I. Demyelinated slices treated with VEH (left) or NEC-1 (right) at 14 dpl immunostained for myelin 
(MBP; red) and axons (NF-H; green). Scale bar, 20 µm. 
J. Remyelination index of VEH- and NEC-1-treated slices at 1, 7 and 14 dpl ± s.e.m.. *P=0.0159, 
**P=0.0079 vs VEH (Mann-Whitney test). N=5 biological replicates per time point and condition.  
K. In vivo microglia-targeting of necrostatin (NEC-1) or vehicle control (Veh) using encapsulation in 
lipidic nanocapsules (LNC), co-injected with LPC into the corpus callosum. 
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L. Uptake of LNCs labelled with DiD (white) primarily by IBA-1+ cells (red) in lesioned corpus 
callosum in vivo, astrocytes (GFAP+) labelled in green. Scale bar, 10 µm. 
M. 3D rendering of DiD-LNCs (white) internalized within IBA-1+ cells (red), astrocytes (GFAP+) 
labelled in green.  
N. Percentage of DiD+ clusters (DiD-LNCs) in lesioned corpus callosum in vivo co-localized with 
microglia (IBA-1+), astrocytes (GFAP+), or oligodendrocytes (CC1+). ****P<0.0001 (2-tailed 
Student’s t-test). N=3 mice. 
O. Images of in vivo lesions at 3 dpl subsequent to treatment with Veh LNCs or NEC-1 LNCs, stained 
for IBA-1 (green) and MLKL (red). Scale bar, 10 µm. 
P. Quantification of the number of Tmem119+ cells and percentage of iNOS+CD68+ or Arg-
1+CD68+ (of total CD68+) in 10 dpl in vivo lesions subsequent to treatment with NEC-1 LNCs, 
represented as fold change over values in Veh LNC. *P=0.0395 for Tmem119+ cells, 0.026 for 
percentage of iNOS+CD68+ cells, and 0.0224 for percentage of Arg-1+CD68+ cells (One sample t-
test compared to a hypothetical value of 1). N=3 mice per stain. 
Q. Images of in vivo corpus callosum at 10 dpl (dotted outline) subsequent to treatment with Veh 
LNCs or NEC-1 LNCs stained for myelin protein MAG (white). Scale bar, 20 µm. 
R. Mean MAG pixel intensity in in vivo lesions (with respective background intensity outside the 
lesion subtracted) at 10 dpl following injection with Veh LNCs or NEC-1 LNCs. **P=0.0055 (2-
tailed unpaired Student’s t-test). N=3 mice per condition. 






Fig. 3. Microglia repopulation is associated with remyelination in mouse and human white 
matter and depends on Type-1 interferon signalling.   
A. In vivo lesions of the corpus callosum (dotted line) at 3, 7 and 10 dpl, along with Sham PBS 
control (7 days post-surgery) stained for IBA-1 (green) and Nestin (red) Scale bar, 50µM. Inset at 7 
dpl demonstrates zoom-in of co-localization of stains. 
B. Z-plane orthogonal view of 7 dpl in vivo lesioned corpus callosum stained for Nestin (red) and 
IBA-1 (green) demonstrates co-expression.  
C. Mean percentage co-localization between IBA-1 and Nestin in vivo staining normalized to total 
IBA-1 signal ± s.e.m.. *P=0.0219 7 dpl vs 10 dpl (Kruskal-Wallis test, Dunn’s Multiple Comparison 
post-test). N=3 mice per time point. 
D. Example plot of flow cytometric analysis of proportion of tdTomato+ cells within in vivo lesions 
which are CD11b+ CD45lo at 3, 7, and 10 dpl.  
E. Average percentage of tdTomato (TdT)+ cells ± s.e.m. which are CD11b+ CD45lo at 3, 7, and 10 
dpl in vivo. *P=0.0496 (One way ANOVA with post-hoc test). N=3 mice per time point. 
F. Average percentage of CD11b+ CD45lo cells ±s.e.m. which are tdTomato+ at 3, 7, and 10 dpl in 
vivo. N=3 mice per time point. 
G. Example plot of flow cytometric analysis of proportion of CD11b+ CD45lo cells which are 
tdTomato+ within in vivo lesions at 3, 7, and 10 dpl, compared to Sham PBS control. 
H. Mean density of MLKL+ microglia (CD68+) per mm2 in control, active, chronic inactive and 
remyelinated MS lesions. Individual data points represent separate lesions (see Supplementary Table 
3). *P=0.0226 active lesions vs control (Mann-Whitney test).  
I. Mean density of RIPK3+ microglia (CD68+) per mm2 in control, active, chronic inactive and 
remyelinated MS lesions. Individual data points represent separate lesions (see Supplementary Table 
1). *P=0.0357 active lesions vs control (Mann-Whitney test).  
 
  387 
24 
 
J. Mean density of Nestin+ PU.1+ cells per mm2 in control, active, chronic inactive and remyelinated 
lesions. Individual data points represent separate lesions (see Supplementary Table 3). *P=0.0286 
active lesions vs control (Mann-Whitney test).  
K. Control brain tissue and active MS lesion immunostained for CD68 (blue) and RIPK3 (red), 
counterstained with Hoechst (turquoise). Scale bar, 20 μm.   
L. Control brain tissue and active MS lesion immunostained for PU.1 (blue) and Nestin (red), 
counterstained with Hoechst (turquoise). Scale bar, 20 μm.   
M. In vivo remyelinating lesions at 3, 7, and 10 dpl immunostained for CD68 (red) and IFNAR2 
(green), counterstained with Hoechst (blue). Inset, rabbit primary isotype control. Scale bar, 10 μm. 
N. In vivo remyelinating lesions at 3, 7, and 10 dpl immunostained for PU.1 (red) and phospho-
STAT1 (green), counterstained with Hoechst (blue). Scale bar, 25 μm. 
O. Representative image of focal in vivo lesion at 7 dpl immunostained for PU.1 (red) and phospho-
STAT1 (green), counterstained with Hoechst (blue). White square corresponds to panel N. Scale bar, 
25 μm. 
P. Mean number of microglia (PU.1+) per field ± s.e.m. in ex vivo brain explants at 1 and 7 dpl, 
treated with anti-IFNAR2 neutralizing antibody or IgG control. N=3 per time point. **P=0.0098 Goat 
IgG 1dpl vs 7 dpl; *P=0.0103 Goat IgG 7 dpl vs anti-IFNAR2 IgG 7 dpl; One-way ANOVA and 
Sidak’s multiple comparison, N=3 per time point. 
Q. Ex vivo brain explants at 7 dpl treated with anti-IFNAR2 IgG or control IgG, immunostained for 
PU.1 (red) and counterstained with Hoechst (blue). Scale bar, 10 μm. 
R. Mean remyelination index of ex vivo brain explants at 7 dpl ± s.e.m. treated with anti-IFNAR2 IgG 
or control goat IgG. *P=0.0252, 2-tailed Student’s t-test. N=3 per condition. 
S. Ex vivo brain explants at 7 dpl treated with anti-IFNAR2 IgG or control Goat IgG, immunostained 
for myelin basic protein (MBP; red) and neurofilament-H (NF; green), showing healthy early 
remyelination in control and debris in anti-IFNAR2 IgG treatment. Scale bar, 10 μm. 
 
 
